Getting Medical Cannabis in Germany: How the System Works

Germany has become one of Europe's most significant markets for legal medical cannabis, with tens of thousands of patients now accessing treatment through a structured, prescription-based framework that was substantially reformed by landmark federal legislation. Understanding how that system works — and whether you qualify — is essential before booking an appointment or crossing a border with medication.

The legislative changes that reshaped German cannabis law created new pathways for both recreational decriminalisation and medical access, but the two streams operate under entirely separate rules. For patients, the medical route remains the most legally secure and clinically supported option available, governed by federal narcotics law and overseen by licensed physicians. (Source: Bundesinstitut für Arzneimittel und Medizinprodukte — BfArM; Deutsche Gesellschaft für Schmerzmedizin)

The Legal Framework: What Changed and What Remains

Germany's overhaul of cannabis regulation did not eliminate the prescription requirement for medical use. Cannabis-based medicines — including dried flower, extracts, and finished pharmaceutical products such as dronabinol and nabilone — remain classified as controlled substances under the Betäubungsmittelgesetz (BtMG), the federal narcotics act. Physicians who prescribe them must hold a valid narcotics prescribing licence, and pharmacies that dispense them must be authorised to handle Schedule III substances. (Source: BfArM)

What the reforms did change is the bureaucratic burden that previously required patients in many cases to seek case-by-case approval from statutory health insurers before a prescription could be reimbursed. The pathway is now more direct for certain conditions, though reimbursement decisions still rest substantially with individual insurers and clinical justification remains mandatory.

For a broader contextual overview of how Germany reached this point, including the political debates and phased implementation, Germany Cannabis Revolution: Everything You Need to Know provides a detailed patient-focused guide to the full legislative timeline.

Recreational Decriminalisation vs. Medical Access

A critical distinction that trips up many patients — particularly those arriving from outside Germany — is the difference between decriminalised recreational possession and medically prescribed use. Adults may currently possess limited quantities of cannabis under the recreational provisions, but that does not grant any right to bring cannabis purchased abroad into Germany, nor does it affect how medical prescriptions are written, filled, or reimbursed. The medical system operates on a completely separate legal track.

Who Can Prescribe and Where to Start

Any licensed physician in Germany with a valid narcotics prescribing authorisation may, in principle, write a prescription for a cannabis-based medicine. There is no requirement that the prescribing doctor be a specialist, though in practice, most prescriptions are issued by specialists in pain medicine, neurology, oncology, psychiatry, or palliative care, where the clinical evidence base is strongest. (Source: Kassenärztliche Bundesvereinigung — KBV)

General practitioners may also prescribe, though their willingness varies considerably. Patients who find their GP reluctant are typically advised to seek a referral to a pain clinic or specialist practice with documented experience in cannabinoid medicine. A growing number of dedicated cannabis clinics — operating through telemedicine as well as in-person consultations — now serve the German market directly.

Telehealth Prescribing in Germany

Remote consultations with licensed German physicians are legally permissible for cannabis prescriptions, provided the platform operates under German medical law and the prescribing doctor holds the appropriate narcotics licence. Patients must still provide full medical history documentation, and the physician is obligated to conduct a thorough clinical assessment before issuing any prescription. Platforms that bypass this process — for example by issuing prescriptions without a genuine clinical review — operate outside the law and expose patients to significant legal and health risk.

Qualifying Conditions: What the Evidence Supports

German medical guidelines do not restrict cannabis prescriptions to a rigid enumerated list in the same way that some other jurisdictions do. Instead, the framework asks physicians to apply clinical judgement, weighing the potential benefits of cannabinoid treatment against other available therapies. In practice, however, certain diagnostic categories account for the overwhelming majority of prescriptions issued. (Source: BfArM prescription data; Deutsche Schmerzgesellschaft)

• Chronic pain — particularly neuropathic pain unresponsive to conventional analgesics
• Multiple sclerosis — specifically spasticity, where nabiximols (Sativex) holds European regulatory approval
• Chemotherapy-induced nausea and vomiting — where standard antiemetics have proved insufficient
• Palliative care — symptom management in terminal illness, including appetite stimulation
• Treatment-resistant epilepsy — particularly in paediatric cases involving Dravet or Lennox-Gastaut syndromes, where cannabidiol (Epidyolex) is licensed
• Severe anxiety disorders — considered on a case-by-case basis, with cautious prescribing due to the psychiatric risk profile of high-THC products
• PTSD — an emerging area with growing clinical literature, though evidence quality remains an active subject of debate
• Sleep disorders secondary to another qualifying condition — typically not prescribed as a primary indication

Patients considering whether their diagnosis may qualify under comparable systems elsewhere may find it useful to review Medical Cannabis UK: Which Conditions Actually Qualify?, which provides condition-by-condition analysis of the evidence landscape — much of which is directly applicable to the German clinical context.

Conditions Where Evidence Remains Weak

Prescribers in Germany are expected to consider whether conventional treatments have been adequately trialled before turning to cannabis-based medicines. For conditions such as general anxiety, insomnia without an underlying diagnosis, or lifestyle-related complaints, the clinical bar for prescription is considerably higher and reimbursement is far less likely. The WHO has noted that while cannabinoids show promise across several therapeutic areas, the overall evidence base remains limited by the historically restricted research environment, and many trials are small or short-duration. (Source: WHO Expert Committee on Drug Dependence)

How Health Insurance Interacts With Your Prescription

Germany's statutory health insurance system — the gesetzliche Krankenversicherung (GKV) — covers cannabis-based medicines under specific conditions, but approval is not automatic. Patients covered by GKV must typically demonstrate that conventional therapies have failed or are contraindicated, that there is a reasonable expectation of benefit, and that a specialist or experienced physician supports the prescription. Insurers may request additional documentation or arrange an independent medical review. (Source: GKV-Spitzenverband)

Privately insured patients generally face fewer prior-authorisation hurdles, though policy terms vary and patients are advised to check their specific contract before assuming coverage. Out-of-pocket costs for cannabis flower or extracts without insurance coverage can be substantial, particularly for conditions requiring higher daily doses.

Challenging an Insurance Refusal

Patients whose reimbursement applications are denied have the right to appeal within the statutory system. Appeals must typically be lodged within four weeks of the written refusal, and patients are entitled to request a review by the Medizinischer Dienst (MD), the independent medical advisory service for statutory insurers. Legal aid organisations and patient advocacy groups in Germany provide guidance on navigating this process at no cost.

Bringing Cannabis Medicine Across Borders

Patients travelling to Germany with a valid prescription issued in another country — or German patients travelling abroad — face a separate and complex regulatory layer. Germany is a signatory to the Schengen Convention, and the import of narcotic substances, including prescribed cannabis, is regulated under both federal law and international treaty obligations. Patients crossing EU internal borders with cannabis medication must typically carry an official Schengen certificate issued by their home country's competent authority, alongside their original prescription. (Source: Bundesministerium für Gesundheit)

Patients from outside the EU — including those visiting from the United States — should be particularly cautious. For a practical breakdown of how US-issued medical cannabis authorisations interact with travel to other jurisdictions, Medical Marijuana in the US as a Foreign Visitor: What Actually Works provides country-specific guidance that is directly relevant to inbound travellers from North America.

Comparing the German and UK Systems

Both Germany and the United Kingdom operate physician-led, prescription-based frameworks for medical cannabis, but they differ meaningfully in their reimbursement structures, prescriber access, and approved product ranges. In the UK, specialist physician prescribing is required in all cases, and NHS reimbursement is available only for a narrow set of licensed products — cannabis flower, for example, is prescribed privately in the UK and is not reimbursed by the NHS. (Source: NICE Technology Appraisals; NHS England)

UK patients exploring their options — whether domestically or considering treatment abroad — may find practical value in How to Get Medical Cannabis in the UK: The Complete Process, which walks through the referral pathway, clinic options, and cost considerations in detail. For those specifically evaluating clinical providers, Best Medical Cannabis Clinics in the UK: What American Patients Should Know offers a structured assessment of what to look for when choosing a clinic.

What to Expect at Your First Appointment

A first consultation with a German physician for cannabis prescribing is a clinical encounter, not a formality. Patients should arrive prepared with comprehensive medical records, including prior diagnoses, treatment history, current medications, and documentation of any adverse reactions to conventional therapies. The physician will assess contraindications — including personal or family history of psychosis, severe cardiovascular disease, pregnancy, and substance use disorder — before proceeding. (Source: Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde)

• Bring all relevant medical records, ideally translated into German or English
• Document all medications currently taken, including supplements and over-the-counter products
• Be prepared to describe previous treatments and their outcomes in specific terms
• Disclose any personal or family psychiatric history honestly — this protects your safety, not just your eligibility
• Ask the prescriber which specific product formulation they recommend and why
• Confirm whether the prescription will be submitted to your insurer before or after dispensing
• Understand that dose titration is typically gradual — effects may not be immediate

Germany's medical cannabis framework is among the most sophisticated and patient-accessible in Europe, but it functions as a clinical system, not a permissive workaround. Patients who approach it through proper medical channels — with honest disclosure, documented clinical need, and realistic expectations about what cannabinoid medicines can and cannot achieve — are best positioned to navigate the process successfully and safely. Those seeking a quick or casual prescription will find the system resistant by design, and rightly so.